New indication


Colin Kerr
Published: Wednesday, May 1, 2019
ILUVIEN® has been approved for use in UK patients for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
“This indication for ILUVIEN was based on data from two three-year, double-masked, prospective sham-controlled studies, PSV-FAI-001 and PSV-FAI-005, in 282 patients with NIU-PS, randomised 2:1 (ILUVIEN:sham). Published data from the PSV-FAI-001 study have shown ILUVIEN to be superior when compared to treated sham for multiple study outcomes, including the primary outcome of recurrence of NIU-PS at six months (27.6% ILUVIEN vs 90.5% sham, p<0.001),” said a spokesman for Alimera Sciences, manufacturers of ILUVIEN.
alimerasciences.com
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.